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developed to project lifetime costs and beneﬁts of lipid therapy.
Clinical trial data were used to estimate LDL-C reductions for
different treatment strategies. Effect of LDL-C reductions on
CHD event rates was estimated using Framingham equations
and Spanish Instituto Nacional de Estadística data on nonCHD-
related mortality. Direct costs of CHD events in Spain, Spanish
prices for simvastatin, atorvastatin and EZ10 were used to
project lifetime costs. Model was run for a population consist-
ing of all CHD and CHD-equivalent patients started on A10 in
an observational Lipid Lowering Treatment study conducted in
Spain, and not at LDL-C goal after 60 days of treatment.
RESULTS: For these patients N = 54 (mean age 62.5 years,
64.8% male, lipid proﬁle on A10 mean LDL-C 148.7mg/dl, 
TC 225.9mg/dl, HDL 45.9mg/dl), switching to EZ10 co-
administered with S20 compared to atorvastatin titration is pro-
jected to increase the life expectancy from 15.99 to 16.31 years
for CHD patients and from 18.11 to 18.23 years for CHD equiv-
alent patients with a discounted incremental cost per life year
gained of 7,855 EURO for CHD patients and 15,356 for CHD
equivalent patients. CONCLUSION: Switching to EZ10 co-
administered with simvastatin for CHD and CHD equivalent
patients not at goal on atorvastatin is projected to be a cost-
effective alternative to atorvastatin titration.
PCV36
ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD
EVENTS WITH STATINS IN ITALY
Bustacchini S1, Ruffo P1, Mantovani LG2
1Pﬁzer Italia srl, Rome, Italy; 2University of Milan, Milan, Italy
OBJECTIVES: Cardiovascular diseases (CVD) are the leading
cause of morbidity and mortality. Treatment with statins has
shown to be effective in controlling cholesterol levels in dyslipi-
demic subjects and in preventing CVD. The objective of this
analysis was the evaluation of the economic impact of the CVD
primary prevention with statins in Italy. METHODS: Alterna-
tives: market mix for statins (low dosages assumed as initial
dosages) marketed in Italy (weighted with the current market
shares) compared with no intervention. Population: sample of
high-risk subjects with an absolute CV risk level ≥ 2% per year,
derived from a population study conducted in the Verona area
in Italy. Perspective: National Health Service (NHS). Technique:
cost-effectiveness analysis, making economic and health projec-
tions in a hypothetical cohort of 1000 subjects in primary pre-
vention; an incremental cost per life year gained (ICER LYG) has
been calculated. Time: 10 years. Costs: drugs and direct medical
costs quantiﬁed in using NHS tariffs expressed in Euro 2003.
Effects: the effects of different statins in controlling cholesterol
levels, as measured with the CURVES study (Jones P et al, 1998)
has been used to model coronary (CHD) morbidity and mortal-
ity from CVD with the Framingham risk equations (Anderson
KM et al, 1990). RESULTS: A primary CVD preventive inter-
vention with statins in a hypothetical cohort of 1000 high-risk
subjects can avoid 70 CHD events and 28 CVD deaths, thus 
projecting 138 LYG. After having considered costs for drugs
(4,789,542€) and savings due to events avoided (319,722€), the
net cost of the intervention is 4,469,820€ with a ICER LYG of
32,458€. CONCLUSIONS: The cost-effectiveness proﬁle of
CVD primary preventive intervention with statins is in the range
of what is considered cost-effective in absolute values by the 
scientiﬁc community.
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OBJECTIVES: To estimate—from the German SHI perspec-
tive—economic consequences of using the low-molecular-weight
heparin enoxaparin subcutaneously (ENOX) instead of intra-
venous unfractionated heparin followed by oral phenprocoumon
(UFH/PPC) for anticoagulation in patients undergoing TEE-
guided early electrocardioversion from nonvalvular atrial ﬁbril-
lation (AF). METHODS: As ENOX is noninferior to UFH/PPC
in preventing deaths and ischemic, embolic, and hemorrhagic
events [Stellbrink C, et al. ACE trial. Circulation 2004], a cost-
minimization analysis (CMA) was performed. The target 
variable “incremental cost for ENOX versus UFH/PPC” was
quantiﬁed using a modelling approach based on decision-tree
technique. The CMA encompassed 28 (26–30) treatment days
with phase I of 5 (3–8) days comprising diagnostics, initiation of
anticoagulation, and cardioversion. Phase II with the remaining
days comprised continued anticoagulation. Resource use was
veriﬁed by a survey in the in- and outpatient sectors. Costs 
were given by SHI expenses and were quantiﬁed by multiplying
utilised resource items by the price or tariff of each item, accord-
ing to German Health Care regulations. RESULTS: In the base-
case analysis, phase I was outpatient based for the majority of
ENOX patients opposed to inpatient treatment for all UFH/PPC
patients, whereas phase II was entirely outpatient based for both
patient groups. There were savings of 579€ per patient with
ENOX (892€) compared to UFH/PPC (1471€). Comprehensive
sensitivity analyses (impact analysis, Monte Carlo simulation)
showed the robustness of the model. Expenses for the inpatient-
based phase I with UFH/PPC had by far the greatest inﬂuence
on the extent of savings obtained. Simultaneous random varia-
tion of all model parameters within their empirically given inter-
vals revealed savings obtained by ENOX in 93% of 10,000
simulated comparisons versus UFH/PPC. CONCLUSIONS: In
TEE-guided early electrocardioversion of nonvalvular AF, anti-
coagulation with ENOX offers SHI in Germany an enormous
saving potential when used instead of UFH/PPC.
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OBJECTIVE: To calculate costs for patients with myocardial
infarction (MI) in common medical practice in Russian Federa-
tion. METHODS: Data on resource use for hospital treatment
of patients with acute myocardial infarction were extracted from
99 medical charts at 3 hospitals at Moscow, Tula and Vladimir.
Data on resource use for out-patient follow-up for patients after
acute myocardial infarction were identiﬁed according to experts’
opinion. A total of 12 experts ﬁlled in the questionnaire for iden-
tifying typical follow-up strategy for 1.5 years after MI. Direct
medical costs were calculated on the basis of price-lists for
medical services and median prices for drugs given in a whole-
sale pharmaceutical informational bulletin. RESULTS: Median
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cost for acute period of MI at hospital was 25,340.00 rubles
($794.36) per patient. There was no signiﬁcant difference
between 3 hospitals. Median total cost for follow-up period in
ﬁrst 6 months after MI was 28,706.63 rubles ($899.89) per
patient for services and drugs mentioned by experts. Median cost
for second 6 months was 11,626.71 rubles ($364.47) per patient;
each 6 months after it required 10,722.73 rubles ($336.14).
CONCLUSION: Costs are relatively low because of rare use of
expensive technologies: only 15% of patients received throm-
bolytical therapy; no coronary artery bypass surgery or stent
implantation were used.
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OBJECTIVES: To estimate the long-term economic and health
impact of managing bradycardia due to sinoatrial node disease
or atrioventricular block with a dual chamber (DDD or DDDR)
vs. single-chamber ventricular pacemaker (VVI or VVIR).
METHODS: A discrete event simulation of 2 identical cohorts
of 1000 patients for 5 years after implantation tracks develop-
ment of post-operative complications, severe pacemaker syn-
drome leading to replacement, atrial ﬁbrillation (which may
become chronic and require anticoagulants), and stroke. Life
expectancy is assumed the same with either device. Risk func-
tions were developed for each device based on two long-term
randomized trials (Canadian Trial of Physiological Pacing,
CTOPP and Mode Selection Trial in Sinus-Node Dysfunction,
MOST). Sensitivity analyses were completed for key input para-
meters. Direct medical costs to the NHS are reported in 2003
British Pounds Sterling (GBP). Beneﬁts were discounted at 1.5%,
and costs 6%. RESULTS: Overall, 29.1% in each cohort died
within 5 years of the implant. Post-operative complications
requiring reoperation increased from 6.4% for VVI(R) to 7.7%
with DDD(R), atrial ﬁbrillation dropped from 22% to 18%;
severe pacemaker symptoms developed in 16.8% with VVI(R)
leading to a wish to switch to DDD(R). Total costs over 5 years
were about 4300 GBP per patient in either cohort. Based on 
100 replications, additional health beneﬁts from DDD(R) are
achieved with a mean net cost of 43 GBP per patient, and 
0.09 QALY gained: a mean cost-effectiveness ratio of 477 GBP
per QALY. In 26% of the replications, however, dual chamber
dominates single chamber. CONCLUSIONS: Whilst implanting
the DDD(R) increases the cost of the initial implantation, this is
predicted to be largely offset by a reduction in long-term 
complications when compared with VVI(R).
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OBJECTIVE: To calculate costs for patients with ischemic stroke
(IS) in common medical practice in Russian Federation.
METHODS. Data on resource use for hospital treatment of
patients with IS were extracted from 70 medical charts at 2 hos-
pitals at Moscow. Data on resource use for out-patient follow-
up for patients after acute myocardial infarction were identiﬁed
according to experts’ opinion. Six experts ﬁlled in the question-
naire for identifying typical follow-up strategy for 1.5 years after
MI. Direct medical costs were calculated on the basis of price-
lists for medical services and median prices for drugs given in a
wholesale pharmaceutical informational bulletin. RESULTS:
Median cost for acute period of IS at hospital was 25,187.00
rubles ($789.56) per patient. There was some difference in costs
between 2 hospitals, but no statistical signiﬁcance was found.
Computer tomography was performed only in 38% patients
(mostly at one hospital). Median total cost for follow-up period
in ﬁrst 6 months after IS was 42,644.50 rubles ($1336.82) per
patient for services and drugs mentioned by experts. Median 
cost for second 6 months was 13,561.08 rubles ($425.11) per
patient; each 6 months after it required 9996.69 rubles
($313.38). CONCLUSIONS: According to experts’ opinion
carotid endarterectomy is performed in no more than 10%
patients after IS.
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OBJECTIVES: Pharmaceutical treatment of hypercholes-
terolemia is recommended in individuals with a LDL-cholesterol
level of ≥190mg/dl and 130–189mg/dl plus two other coronary
heart disease risk factors or a coronary heart disease risk >20%
in 10 years. The objective of this study was to assess the 
cost-effectiveness of pharmaceutical treatments of hypercholes-
terolemia in Catalonia, Spain. METHODS: Treatments evalu-
ated included 20, 40, and 80mg/day of lovastatin and
ﬂuvastatin, 10, 20, and 40mg/day of pravastatin, simvastatin
and atorvastatin, 12 and 24g/day of cholestyramine, and 
1.2g/day of gemﬁbrozil. The cost-effectiveness was evaluated
comparing annual treatment costs and the percentage of LDL-
cholesterol reduction. Treatment costs included medication,
medical visits control measures, and treatment of secondary
adverse effects. Wholesale prices in 2002 were used to estimate
medication costs. A metanalysis was carried out to estimate
effectiveness of different treatments, including all published ran-
domized, double blind clinical trials referred on Medline from
1991 to 2002. RESULTS: The annual cost of medication ranged
from 332.98€ for 20mg/day lovastatin to 1105.17€ for 
40mg/day atorvastatin. The percentage of LDL-cholesterol
reduction ranged from 10% for 12g/day cholestyramine to 49%
for 80mg/day atorvastatin. The average cost-effectiveness ratios
in terms of € per one per cent of LDL-cholesterol reduced were
11.22€–22.55€ for atorvastatin, 12.00–21.96€ for simvastatin,
13.87–21.64€ for lovastatin, 15.24–24.69€ for ﬂuvastatin,
20.96–41.77€ for pravastatin, 32.61€ for gemﬁbrozil, and
35.21–45.55€ for cholestyramine. The incremental cost-
effectiveness analysis showed that the more efﬁcient cholesterol-
lowering therapies were 10mg/day atorvastatin, 10mg/day 
simvastatin, 20mg/day lovastatin, 20mg/day ﬂuvastatin, and 20,
40 and 80mg/day atorvastatin. CONCLUSIONS: Efﬁcient statin
therapies detected in this study should be the ﬁrst election cho-
lesterol-lowering drugs used in patients with hypercholes-
terolemia in Catalonia.
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OBJECTIVE: Research has shown that most smokers start
before the age of 18 and after that age the probability to start-
ing smoking decreases steadily. Furthermore, smokers who start
earlier in life are less likely to quit and reducing or delaying 
initiation could have a large impact on public health. In 2002,
